Eletriptan Hydrobromide

Acute migraine is the target of eletriptan hydrobromide, which constricts the dilated cranial blood vessels associated with an attack and interrupts pain transmission within central pathways. The dual action on vascular calibre and on nociceptive signalling is characteristic of the triptan class and separates these agents from simple analgesics. Choosing the hydrobromide salt supports reliable absorption after oral administration, the practical requirement for an agent taken at the onset of an attack. The salt has the formula C22H27BrN2O2S and a molecular weight of approximately 463.4 g/mol. It is an approved small-molecule agent that has completed the final phase of clinical development.

SMILES

Br.CN1CCC[C@@H]1Cc1c[nH]c2ccc(CCS(=O)(=O)c3ccccc3)cc12

InChI

InChI=1S/C22H26N2O2S.BrH/c1-24-12-5-6-19(24)15-18-16-23-22-10-9-17(14-21(18)22)11-13-27(25,26)20-7-3-2-4-8-20;/h2-4,7-10,14,16,19,23H,5-6,11-13,15H2,1H3;1H/t19-;/m1./s1